Metformin in Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

Also called NCT02252081

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 125 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02252081
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02252081. Randomized; quadruple masking; primary purpose treatment. Start 2014-10-01 (actual); primary completion 2019-12-31 (actual). Results posted on 2021-11-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin in Kidney Disease
Condition
Cardiovascular Disease
Intervention (Drug)
metformin
Intervention (Drug)
Placebo
Lead sponsor
VA Office of Research and Development (class: US federal agency)

Record details

Record id
cardio:ct-nct02252081
Content hash
ceaa095e831c57c3760820b80b450a214563a078406db053e754641c1b21f269